Dr. Agarwal’s Eye Hospital Ltd approves Scheme of Amalgamation effective Nov 1, 2026
Dr Agarwals Eye Hospital Ltd · Healthcare Services
What the filing says
- NCLT sanctioned the Scheme of Amalgamation with Dr. Agarwal’s Health Care Ltd, effective Nov 1, 2026, appointed date Apr 1, 2026
- Record Date set for Nov 18, 2026 for allotment of shares at ratio of 23 shares of Health Care Ltd for every 2 shares of Eye Hospital Ltd
- Board of Directors will dissolve automatically on Nov 1, 2026; company status to change to Amalgamated without further actions
Why it's rated notable: no figure in the filing to size it as major
Figures checked against the filing by a second AI read. About the business, not the share price.
Original filing
Board Meeting Outcome for Material Update On The Scheme Of Amalgamation Between Dr. Agarwals Eye Hospital Limited And Dr. Agarwals Health Care Limited And Their Respective Shareholders And Creditors
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Electrical Equipment
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Dr Agarwals Eye Hospital Ltd
- Acquisition / mergerNotableNCLT sanctions Dr. Agarwal's Eye Hospital amalgamation into Dr. Agarwal's Health Care
Other acquisition / merger filings this fortnight
- Sudarshan Europe B.V. discloses substantial acquisition in Heubach Colorants India Ltd
- Sagility Limited acquires Chirok Health to expand provider-focused services
- Shrem InvIT manager's board approves up to INR 1,046 crore NaBFID term loan
- Dr. Agarwal's Health Care board notes amalgamation scheme effective Nov 1, 2026
- Kwality Pharmaceuticals acquires 4 acres for manufacturing expansion in Amritsar
- EPL Limited receives no-objection letters from BSE and NSE for Scheme of Amalgamation
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.